Welcome to our dedicated page for Forte Biosciences SEC filings (Ticker: FBRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Forte Biosciences, Inc. filings document a clinical-stage biopharmaceutical issuer focused on FB102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for autoimmune and autoimmune-related diseases. Its 8-K reports cover operating and financial results, Regulation FD clinical disclosures, material events, capital-structure matters and exhibits such as press releases and clinical presentations.
Proxy materials describe annual meeting matters, stockholder voting, board and compensation governance and equity incentive plan administration. The filing record also identifies Forte’s common stock, par value $0.001 per share, listed on Nasdaq under the symbol FBRX.
Forte Biosciences, Inc. reported that Chief Financial Officer Antony A. Riley received a grant of stock options covering 22,000 shares of common stock. The options have an exercise price of $17.15 per share and expire on June 16, 2036.
According to the disclosure, all 22,000 option shares were held directly after the transaction, reflecting a compensation-related award rather than an open-market purchase. The footnotes state that, subject to continued service, one forty-eighth of the options will vest monthly starting on the Vesting Commencement Date of June 16, 2026, so the grant is scheduled to be fully vested four years after that date.
Forte Biosciences director and officer Paul A. Wagner received a grant of stock options for 500,000 shares of Common Stock. The options have an exercise price of $17.15 per share and expire on June 16, 2036. This is a compensation-related award, not an open-market purchase.
According to the vesting terms, beginning on the Vesting Commencement Date of June 16, 2026, one forty-eighth of the options vest each month, so the award becomes fully vested over four years if he continues as a service provider.
Forte Biosciences (Common Stock): A joint Schedule 13G filing states that Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander report shared voting and dispositive power over 1,062,182 shares, representing 5.2% of the class, with the cover date 06/04/2026. The filing explains these shares are held by entities subject to voting control and investment discretion by Millennium Management LLC and related managers. The filers executed a Joint Filing Agreement dated June 5, 2026 and provided the issuer address at 3060 Pegasus Park Drive, Building 6, Dallas, Texas 75247.
Forte Biosciences, Inc. amends its Form S-3 shelf registration to register up to $500,000,000 of securities to be offered from time to time, including common stock, preferred stock, debt securities, depositary shares, warrants, subscription rights, purchase contracts and units.
The prospectus updates incorporated documents and describes that specific terms and offering mechanics will be provided in prospectus supplements; proceeds treatment will be set forth in those supplements.
Doberstein Stephen K reported acquisition or exercise transactions in this Form 4 filing.
Forte Biosciences, Inc. director Stephen K. Doberstein received a grant of 18,353 Restricted Stock Units (RSUs) tied to the company’s common stock. Each RSU represents the right to receive one share of Forte Biosciences common stock.
All 18,353 RSUs will vest in a single installment on the date of the first annual meeting of stockholders that occurs after May 29, 2026, as long as Doberstein continues to serve as a “Service Provider” under the company’s 2021 Equity Incentive Plan through that date. After this award, he is reported as directly holding 18,353 RSUs.
Forte Biosciences, Inc. filed a shelf registration on to offer up to $500,000,000 of securities, including common stock, preferred stock, debt securities, depositary shares, warrants, subscription rights, purchase contracts and units. The prospectus describes general terms and states specific offering terms will be provided in prospectus supplements.
The company is a clinical-stage biopharmaceutical developer of FB102, an anti-CD122 monoclonal antibody. The filing summarizes clinical progress: completed healthy-volunteer Phase 1 cohorts, a 32-subject Phase 1b celiac study (24 on FB102, 8 placebo) with reported histologic and symptom benefits, ongoing Phase 1b trials in vitiligo and alopecia areata, a Phase 2 celiac study initiated July 2025 with topline readout expected in 2026, and an FDA IND cleared for a U.S. arm in November 2025.
Forte Biosciences director Shivpreet Singh Kapoor received a grant of 18,353 restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Forte Biosciences, Inc. common stock. The award was granted at no exercise price as equity compensation.
All 18,353 RSUs will vest in a single installment on the date of the first annual meeting of stockholders that occurs after May 29, 2026, provided Kapoor continues to serve as a Service Provider under the company’s 2021 Equity Incentive Plan through that date. Following this grant, Kapoor directly holds 18,353 RSUs tied to an equal number of underlying common shares.
VINCENT RICHARD G reported acquisition or exercise transactions in this Form 4 filing.
Forte Biosciences, Inc. director Richard G. Vincent received a grant of 18,353 restricted stock units (RSUs), each representing a contingent right to one share of common stock. All RSUs will vest in full at the first annual stockholder meeting occurring after May 29, 2026, if he continues as a service provider.
GRYSKA DAVID W reported acquisition or exercise transactions in this Form 4 filing.
Forte Biosciences, Inc. director David W. Gryska received a grant of 18,353 restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Forte Biosciences common stock.
The RSUs will fully vest in a single installment on the date of the first annual meeting of stockholders that occurs after May 29, 2026, as long as Gryska continues to serve as a Service Provider under the company’s 2021 Equity Incentive Plan. Following this award, he directly holds 18,353 RSUs, with no open-market purchases or sales reported in this filing.